Since 2019, the SARS-CoV-2 pandemic has caused a huge chaos throughout the world and the major threat has been possessed by the immune-compromised individuals involving the cancer patients; their weakened immune response makes them vulnerable and susceptible to the virus. The oncologists as well as their patients are facing many problems for their treatment sessions as they need to postpone their surgery, chemotherapy, or radiotherapy. The approach that could be adopted especially for the cancer patients is the amalgamation of immunotherapy and nanotherapy which can reduce the burden on the healthcare at this peak time of the infection. There is also a need to predict or analyze the data of cancer patients who are at a severe risk of being exposed to an infection in order to reduce the mortality rate. The use of artificial intelligence (AI) could be incorporated where the real time data will be available to the physicians according to the different patient’s clinical characteristics and their past treatments. With this data, it will become easier for them to modify or replace the treatment to increase the efficacy against the infection. The combination of an immunotherapy and nanotherapy will be targeted to treat the cancer patients diagnosed with SARS-CoV-2 and the AI will act as icing on the cake to monitor, predict and analyze the data of the patients to improve the treatment regime for the most vulnerable patients.
In this study, we employed liquid chromatography–tandem mass spectrometry (LC–MS/MS) to perform chemo-profiling on four fungal species: three Trichoderma species—two strains of Trichoderma asperellum (S3-3 and S3-1) and one Trichoderma longibrachiatum (FS-46)—and one species from the Tolypocladium genus, Tolypocladium inflatum (MTCC-3538). Our analysis identified 78 peptaibols featuring α-aminoisobutyric acid (Aib). Among these, we discovered both cyclic and linear Peptaibols and lipopeptaibols with Aib, ranging in putative molecular weights from 1033.4 to 1953.6 g/mol, corresponding to peptide lengths of 10-20 amino acids. In total, 78 peptaibols, including lipopeptaibols, were identified through LC-MS/MS. Of these, 43 were recognized as new peptaibols based on mass fragmentation patterns and sequence data from the MS/MS analysis. Our findings suggest that LC-MS/MS-based large-scale studies of the peptaibiome will facilitate the discovery of novel peptaibols and provide a valuable reference for understanding the fragmentation patterns of peptaibols, cyclic peptaibols, and lipopeptaibols.